alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 576–600 of 612 studies with an author at Johns Hopkins University (US) (page 24 of 25) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Associations between joint air pollution exposure, mental health, and physical health and dementia incidence in an aging U.S. cohort

✓ Peer-reviewed alzhub usefulness score 39 out of 100. The Journals of Gerontology Series B 2025-12-30

We found significant associations between ADRD risk and particulate matter <2.5 µm in diameter and nitrogen dioxide in women. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

HOME HEALTH USE BY OLDER ADULTS WITH DEMENTIA: COMPARING MEDICARE ADVANTAGE AND TRADITIONAL MEDICARE

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Innovation in Aging 2024

Skilled home health care (HHC) is a critical service for community-dwelling older adults with dementia, but the majority of evidence about its use and quality is based on Traditional Medicare (TM) beneficiaries. 1 key finding →

Participants: 316,407 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Glutamate as a hippocampal neuron survival factor: an inherited defect in the trisomy 16 mouse

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Proceedings of the National Academy of Sciences of the United States of America 1995-10-01

The survival of cultured mouse hippocampal neurons was found to be greatly enhanced by micromolar concentrations of the excitatory neurotransmitter glutamate. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Exploring Neighborhood Level Socioeconomic Status and Volumetric MRI Results in Patients with Memory Impairment

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2024-12-01

Contrary to expectations, high versus low ADI groups only showed a difference in hippocampal volume, but in the reverse direction. 4 key findings →

Participants: 310 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The potential impact of optimal blood pressure treatment intensity to reduce disparities in dementia between Black and White individuals

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Alzheimer s Disease 2025-01-01

average annual dementia incidence in White, but not Black, adults (1% versus 0%), due to hypertensive individuals' greater survival, and reduce annual ASCVD events more in Black than White adults (13% versus 5%). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Growth of Fee-for-Service Medicare Home-Based Medical Care Within Private Residences and Domiciliary Care Settings in the U.S., 2012-2019

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of the American Medical Directors Association 2022-10-07

Home-based medical care (HBMC) delivers physician or advanced practice provider-led medical services for patients in private residences and domiciliary settings (eg, assisted living facilities, group/boarding homes). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Classifying Dementia Diagnoses in the Baltimore Experience Corps Trial Using Medicare and Maryland’s Health Data

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Innovation in Aging 2025-12-01

Centers for Medicare and Medicaid Services (CMS) administrative data are among the most practical sources for understanding the incidence of dementia over time in older populations, but have yet to be widely used in intervention studies. 1 key finding →

Participants: 135 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Artificial intelligence as an emerging technology in the current care of neurological disorders

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of neurology 2019-08-26

The smart device system to monitor tremors and to recognize its phenotypes for better outcomes of deep brain stimulation, applications evaluating fine motor functions, AI integrated electroencephalogram learning to diagnose epilepsy and psychological non-epileptic seizure, predict outcome of seizure surgeries, recognize patterns of autonomic instability to prevent sudden unexpected death in epilepsy (SUDEP), identify the pattern of complex algorithm in neuroimaging classifying cognitive impairment, differentiating and classifying concussion phenotypes, smartwatches monitoring atrial fibrillation to prevent strokes, and prediction of prognosis in dementia are unique examples of experimental utilizations of AI in the field of neurology. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Neuropathology of Down syndrome and Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 36 out of 100. American journal of medical genetics. Supplement 1990-01-01

Patients with Down syndrome (DS) over 40 years of age, prematurely and consistently develop neurofibrillary tangles (NFT), intracytoplasmic inclusions of highly insoluble straight or paired helical 12-16 nm filaments, and senile plaques (SP) composed of abnormal neurites surrounding a core of beta amyloid. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Paving the Way for Therapy: The Second International Conference of the Trisomy 21 Research Society

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Molecular syndromology 2018-10-30

In the last decade, a number of important research advances in different fields have allowed Down syndrome (DS) research to flourish, creating a time of both unparalleled opportunity and considerable challenge. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The role of hippocampal tau protein phosphorylation in isoflurane-induced cognitive dysfunction in transgenic APP695 mice

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Anesthesia and analgesia 2014-08-01

Previous studies have shown that exposure to inhaled anesthetics can cause cognitive dysfunction, suggesting that general anesthesia might be a risk factor for the development of Alzheimer disease. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Promoting Brain Health in the Context of Normal Aging and Mild Cognitive Impairment: A Tutorial

✓ Peer-reviewed alzhub usefulness score 36 out of 100. American journal of speech-language pathology 2026-06-18

There are significant opportunities for speech-language pathologists (SLPs) to play important roles in the primary and secondary prevention of Alzheimer's disease and related dementias (ADRD) beyond current practices. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Analytical and Clinical Validity of a High-Throughput, Fully Automated Immunoassay for Plasma Neurofilament Light Chain

✓ Peer-reviewed alzhub usefulness score 35 out of 100. The Journal of Applied Laboratory Medicine 2026-04-10

The NfL assay met analytical criteria, with precision demonstrating coefficients of variation <3% across runs, a lower limit of quantification of 3.10 pg/mL, linearity with <12% deviation, and <10% interference. 5 key findings →

Participants: 20 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed